I-Mab and Bristol Myers Squibb Tackle Gastric Cancer
Company Announcements

I-Mab and Bristol Myers Squibb Tackle Gastric Cancer

I-MAB (IMAB) has released an update.

I-Mab has announced a partnership with Bristol Myers Squibb to explore a new combination treatment for gastric and esophageal cancers, involving givastomig, an investigational bispecific antibody, nivolumab, and chemotherapy. The collaboration is based on promising data from a previous givastomig monotherapy study and aims to enhance anti-tumor responses in advanced-stage patients. This clinical trial could mark a significant advancement in first-line treatment options for these types of cancer.

For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskI-Mab Appoints New CEO to Drive Cancer Therapy Goals
TheFlyI-Mab names Sean Fu as permanent CEO
TheFlyInhibrx prevails in trade secret case with I-Mab
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App